<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861611</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10026</org_study_id>
    <nct_id>NCT03861611</nct_id>
  </id_info>
  <brief_title>A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain.</brief_title>
  <official_title>A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain. A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: This is a randomized clinical trial comparing the effects of three different
      medications for acute low back pain (LBP):Ketorolac, Ibuprofen, Diclofenac

      Hypothesis: A daily regimen of ketorolac will provide greater relief of LBP than ibuprofen or
      diclofenac 5 days after an emergency department (ED) visit, as measured by the Roland Morris
      Disability Questionnaire (RMQ)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 2.5 million patients present to US emergency departments (ED) annually with low
      back pain. Up to half of ED patients with acute, new onset low back pain (LBP) report
      persistent moderate or severe pain one week after the ED visit. Non-steroidal
      anti-inflammatory drugs (NSAIDs) are an effective treatment of acute LBP, though their impact
      is only modest.Given the poor pain and functional outcomes that persist beyond an ED visit
      for acute LBP, this clinical trial proposes to determine whether there is a difference in
      efficacy between the NSAIDs ketorolac, ibuprofen, and diclofenac and for the treatment of
      acute, non-traumatic, non-radicular low back pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 5 in Functional Impairment</measure>
    <time_frame>Baseline to 5 days</time_frame>
    <description>The change will be assessed by Roland Morris Disability Questionnaire between the baseline ED visit and the five day follow-up. The Roland-Morris Questionnaire (RMQ) is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worsening LBP after ED visit</measure>
    <time_frame>48 hours and 5 days after Emergency department visit</time_frame>
    <description>Worsening LBP over the previous 24 hours, using a four point ordinal scale: severe, moderate, mild, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of LBP after ED visit</measure>
    <time_frame>48 hours and 5 days</time_frame>
    <description>Frequency will be assessed using the five point Likert scale: Not at all, Rarely, Sometimes, Usually, Always</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic or NSAID usage</measure>
    <time_frame>24 hours to 5 days</time_frame>
    <description>Usage of NSAID and analgesic medications</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Back Pain Without Radiation</condition>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac + Educational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen + Educational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac + Educational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed</description>
    <arm_group_label>Ketorolac + Educational Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed</description>
    <arm_group_label>Ibuprofen + Educational Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed</description>
    <arm_group_label>Diclofenac + Educational Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational Intervention</intervention_name>
    <description>Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)</description>
    <arm_group_label>Diclofenac + Educational Intervention</arm_group_label>
    <arm_group_label>Ibuprofen + Educational Intervention</arm_group_label>
    <arm_group_label>Ketorolac + Educational Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age 18-64.

          -  Present to ED primary for management of Low Back Pain (LBP)

          -  Functionally impairing back pain: A baseline score of greater than 5 on the
             Roland-Morris Disability Questionnaire

          -  Musculoskeletal etiology of low back.

          -  Non-radicular pain.

          -  Pain duration &lt;2 weeks (336 hours).

          -  Non-traumatic LBP

          -  Participant is to be discharged home.

        Exclusion Criteria:

          -  Flank pain, that is pain originating from tissues lateral to the paraspinal muscles.

          -  Not available for follow-up

          -  Pregnant

          -  Chronic pain syndrome

          -  Allergic to or intolerant of investigational medications

          -  Contra-indications to investigational medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddie Irizarry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eddie Irizarry, MD</last_name>
    <phone>718-920-6626</phone>
    <email>eddiriza@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Friedman, MD, MS</last_name>
    <phone>718-920-6626</phone>
    <email>befriedm@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddie Irizarry, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eddie Irizarry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Eddie Irizarry</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>ketorolac</keyword>
  <keyword>diclofenac</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>low back pain</keyword>
  <keyword>back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

